Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzona diagnoza chłoniaka z dużych komórek B-limfocytowych
- •Wcześniejsze leczenie co najmniej jednej lub dwóch linii (w zależności od grupy)
- •Choroba powróciła lub nie odpowiada na dotychczasowe leczenie
- •Co najmniej jeden widoczny guz do zmierzenia
- •Ogólny stan zdrowia pozwalający na udział w badaniu
- •Wystarczająca liczba białych krwinek i płytek w krwi
- •Chęć i możliwość udzielenia świadomej zgody
✗ Disqualifies
- •Historia innych nowotworów (poza rakiem skóry) w ciągu ostatnich 3 lat
- •Rak rozprzestrzeniony do mózgu
- •Historia zapalenia mięśnia sercowego związanego z chłoniakiem
- •Stan zdrowia wymagający natychmiastowej opieki medycznej
- •Niedawne chemioterapia lub radioterapia
- •Pozostałe działania niepożądane z poprzedniego leczenia
- •Historia przeszczepu szpiku lub narządu
- •Wcześniejsza terapia komórkami genetycznie modyfikowanymi (z wyjątkiem niektórych wcześniejszych leków anty-CD19)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (35)
University of California-Irvine Medical Center
Irvine, United States
Cedars-Sinai Medical Center
Los Angeles, United States
University of California, Los Angeles (UCLA) Medical Center
Los Angeles, United States
Scripps Clinic
San Diego, United States
Colorado Blood Cancer Institute
Denver, United States
Medstar Georgetown University Hospital
Washington D.C., United States
Augusta University Medical Center
Augusta, United States
Indiana Blood and Marrow Transplantation
Indianapolis, United States
University of Iowa
Iowa City, United States
University of Louisville Brown Cancer Center
Louisville, United States
Louisiana State University Health Sciences Center
Shreveport, United States
Corewell Health
Grand Rapids, United States
University of Nebraska Medical Center
Omaha, United States
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, United States
University of New Mexico Comprehensive Cancer Center
Albuquerque, United States
Roswell Park Comprehensive Cancer Center
Buffalo, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
New York, United States
Montefiore Medical Center
The Bronx, United States
Atrium Health Wake Forest Baptist
Winston-Salem, United States
University of Cincinnati (UC) Physicians Company, LLC
Cincinnati, United States
Cleveland Clinic
Cleveland, United States
Lehigh Valley Topper Cancer Center Institute
Allentown, United States
Thomas Jefferson University
Philadelphia, United States
West Penn Hospital
Pittsburgh, United States
Vanderbilt University Medical Center
Nashville, United States
Baylor University Medical Center
Dallas, United States
Texas Transplant Institute
San Antonio, United States
Huntsman Cancer Institute
Salt Lake City, United States
Intermountain Healthcare
Salt Lake City, United States
Virginia Oncology Associates
Norfolk, United States
Virginia Commonwealth University-Massey Cancer Center
Richmond, United States
Medical College of Wisconsin
Milwaukee, United States
Sir Charles Gairdner Hospital
Nedlands, Australia
Royal Perth Hospital
Perth, Australia
The Alfred Hospital
Melbourne, Australia
Trial contact
Stephen Simko, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.